Author:
Bonner N.,Bozzi S.,Morgan L.,Mason B.,Peterschmitt M. J.,Fischer T. Z.,Arbuckle R.,Reaney M.
Abstract
Abstract
Background
Approximately 7–10% of Parkinson’s disease (PD) patients carry a GBA (Glucocerebrosidase) mutation (GBA-PD patients), which may influence the disease’s clinical course.
Objectives
This study aimed to explore the patient experience of GBA-PD and identify the most important symptoms and impacts to inform clinical trial measurement strategies.
Methods
Twenty PD patients (n = 15 GBA-PD; n = 5 idiopathic-PD) participated in qualitative interviews which explored concepts spontaneously reported or identified through a literature review. Telephone interviews with five expert clinicians included discussion of a preliminary conceptual model derived from literature. Verbatim transcripts were thematically analysed.
Results
Thirty symptoms reported by patients were categorized as motor, non-motor, and cognitive/psychiatric. Tremor (n = 13), memory loss (n = 13), rigidity/stiffness (n = 11), and speech problems (n = 11) were considered the most important and impactful symptoms by GBA-PD patients, although other symptoms were also relevant to the majority of patients. Key impacts included: sleep disturbances (n = 13), handwriting changes (n = 13), reduced social interaction (n = 12), dyskinesia (n = 10), depressed mood (n = 9), and fear of falling (n = 8). Key symptoms and impacts reported by GBA-PD patients were consistent with those reported by idiopathic-PD patients. Clinician interview results supported the patient findings, although some clinicians indicated that cognitive/psychiatric symptoms may present earlier in GBA-PD patients. The concepts emerging from the research informed updates to a conceptual model of GBA-PD patients’ disease experience.
Conclusions
The findings provide in-depth understanding of the patient experience of GBA-PD. The findings confirm that the concepts relevant to assess in GBA-PD are consistent with those relevant to assess in idiopathic-PD; however, greater consideration of cognitive/psychiatric symptoms may be warranted in GBA-PD populations.
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference18 articles.
1. Glaser, B., & Strauss, A. (2010). The constant comparative methods of qualitative analysis. In B. G. Glaser, & A. L. Strauss (Eds.), The discovery of grounded theory: Strategries for qualitative research, (pp. 101–116). New York: Aldine de Gruyter.
2. Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A. K., Schulte, C., Maetzler, W., et al. (2015). GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Movement Disorders, 30(3), 407–411.
3. Klein, C., Schneider, S. A., & Lang, A. E. (2009). Hereditary parkinsonism: Parkinson disease look-alikes—An algorithm for clinicians to “PARK” genes and beyond. Movement disorders: official journal of the Movement Disorder Society, 24(14), 2042–2058.
4. Cox, T. M., Rosenbloom, B. E., & Barker, R. A. (2015). Gaucher disease and comorbidities: B-cell malignancy and parkinsonism. American Journal of Hematology, 90, S25–S28.
5. The Voice of the Patient (2016). A series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative - Parkinson’s disease. Public meeting: September 22, 2015. Silver Spring: Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献